Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978374441> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2978374441 endingPage "S386" @default.
- W2978374441 startingPage "S385" @default.
- W2978374441 abstract "Introduction: Chronic Hepatitis C (CHC) is global epidemic in USA with a prevalence of 2.8%with an incidence of 3.3% in end-stage renal disease (ESRD) in hemodialysis (HD) population. CHC in ERSD with HD has significant higher fibrotic state and accelerated cirrhosis with decompensation and higher rate of hepatocellular carcinoma (HCC). The mortality and hazard ratio of chronic hepatitis C in ESRD on HD with relative risk of death is 1.79% and post renal transplant graft failure is1. 56%. Prior DAA's with Interferon and Ribavirin achieved 63% SVR in 48 weeks Methods: Primary Objective: To show the efficacy of the triple regimen (Paritaprevir, Ritonavir and Ombitasvir) by obtaining SVR12 Secondary Objectives: Safety, tolerability Thirty Six (36) patients (18 cirrhotics and 18 non-cirrhotics) were recruited from 4 dialysis centers across Brooklyn; in patients undergoing hemodialysis with chronic hepatitis C; genotype 1. The patients were divided into two groups: group A (n=18) with cirrhosis and group B (n=18) with no cirrhosis. Group A: Ombitasvir (Abt 267) + Ritanavir + Dastasbuvir (Abt 333) + Prataspravir (Abt 450); with 200 mg daily of RBV Group B: Ombitasvir (Abt 267) + Ritanavir + Dastasbuvir (Abt 333) + Prataspravir (Abt 450); without RBV Results: see table Conclusion: This study demonstrates a high SVR with a very short course DAA's in HCV in patients on HD. Both the groups achieved overall 94.4 % SVR 12. Both groups had one patient with virological failure (5.5 %). A total of 3/36 (8.3%) patients relapsed; 2/18 (11.1%) in group A versus 1/18 (5.5%) in group B. Role of DAA's in ESRD patients on HD in CHILD A cirrhotics have encouraging SVR rates; though carries a risk of higher relapse rate despite daily modified doses of RBV. Overall the drugs were well tolerated with minimal side events and without treatment failure. Triple therapy with RBV is a viable option and larger clinical trials will validate the efficacy and short treatment paradigm. Figure 1" @default.
- W2978374441 created "2019-10-10" @default.
- W2978374441 creator A5003359576 @default.
- W2978374441 creator A5011634142 @default.
- W2978374441 creator A5014765719 @default.
- W2978374441 creator A5018516313 @default.
- W2978374441 creator A5043190728 @default.
- W2978374441 creator A5047365163 @default.
- W2978374441 creator A5078810618 @default.
- W2978374441 date "2016-10-01" @default.
- W2978374441 modified "2023-10-13" @default.
- W2978374441 title "Ombitasvir, Ritanavir Boost with Dastasbuvir and Prataspravir with or without Ribavirin in G1 Special Population in Hemodialysis in Chronic Hepatitis C Patients DROP C Trial: A Prospective Clinical Pilot Study" @default.
- W2978374441 doi "https://doi.org/10.14309/00000434-201610001-00880" @default.
- W2978374441 hasPublicationYear "2016" @default.
- W2978374441 type Work @default.
- W2978374441 sameAs 2978374441 @default.
- W2978374441 citedByCount "0" @default.
- W2978374441 crossrefType "journal-article" @default.
- W2978374441 hasAuthorship W2978374441A5003359576 @default.
- W2978374441 hasAuthorship W2978374441A5011634142 @default.
- W2978374441 hasAuthorship W2978374441A5014765719 @default.
- W2978374441 hasAuthorship W2978374441A5018516313 @default.
- W2978374441 hasAuthorship W2978374441A5043190728 @default.
- W2978374441 hasAuthorship W2978374441A5047365163 @default.
- W2978374441 hasAuthorship W2978374441A5078810618 @default.
- W2978374441 hasConcept C126322002 @default.
- W2978374441 hasConcept C141071460 @default.
- W2978374441 hasConcept C142462285 @default.
- W2978374441 hasConcept C203014093 @default.
- W2978374441 hasConcept C2522874641 @default.
- W2978374441 hasConcept C2776408679 @default.
- W2978374441 hasConcept C2776455275 @default.
- W2978374441 hasConcept C2777100407 @default.
- W2978374441 hasConcept C2777214474 @default.
- W2978374441 hasConcept C2778063415 @default.
- W2978374441 hasConcept C2778721985 @default.
- W2978374441 hasConcept C2778785139 @default.
- W2978374441 hasConcept C2778867932 @default.
- W2978374441 hasConcept C2779298103 @default.
- W2978374441 hasConcept C2780040827 @default.
- W2978374441 hasConcept C2781413609 @default.
- W2978374441 hasConcept C2908647359 @default.
- W2978374441 hasConcept C2993143319 @default.
- W2978374441 hasConcept C3013748606 @default.
- W2978374441 hasConcept C71924100 @default.
- W2978374441 hasConcept C90924648 @default.
- W2978374441 hasConcept C99454951 @default.
- W2978374441 hasConceptScore W2978374441C126322002 @default.
- W2978374441 hasConceptScore W2978374441C141071460 @default.
- W2978374441 hasConceptScore W2978374441C142462285 @default.
- W2978374441 hasConceptScore W2978374441C203014093 @default.
- W2978374441 hasConceptScore W2978374441C2522874641 @default.
- W2978374441 hasConceptScore W2978374441C2776408679 @default.
- W2978374441 hasConceptScore W2978374441C2776455275 @default.
- W2978374441 hasConceptScore W2978374441C2777100407 @default.
- W2978374441 hasConceptScore W2978374441C2777214474 @default.
- W2978374441 hasConceptScore W2978374441C2778063415 @default.
- W2978374441 hasConceptScore W2978374441C2778721985 @default.
- W2978374441 hasConceptScore W2978374441C2778785139 @default.
- W2978374441 hasConceptScore W2978374441C2778867932 @default.
- W2978374441 hasConceptScore W2978374441C2779298103 @default.
- W2978374441 hasConceptScore W2978374441C2780040827 @default.
- W2978374441 hasConceptScore W2978374441C2781413609 @default.
- W2978374441 hasConceptScore W2978374441C2908647359 @default.
- W2978374441 hasConceptScore W2978374441C2993143319 @default.
- W2978374441 hasConceptScore W2978374441C3013748606 @default.
- W2978374441 hasConceptScore W2978374441C71924100 @default.
- W2978374441 hasConceptScore W2978374441C90924648 @default.
- W2978374441 hasConceptScore W2978374441C99454951 @default.
- W2978374441 hasLocation W29783744411 @default.
- W2978374441 hasOpenAccess W2978374441 @default.
- W2978374441 hasPrimaryLocation W29783744411 @default.
- W2978374441 hasRelatedWork W2093485897 @default.
- W2978374441 hasRelatedWork W2193729855 @default.
- W2978374441 hasRelatedWork W2334534169 @default.
- W2978374441 hasRelatedWork W2399748013 @default.
- W2978374441 hasRelatedWork W2582288071 @default.
- W2978374441 hasRelatedWork W2612098812 @default.
- W2978374441 hasRelatedWork W2771990701 @default.
- W2978374441 hasRelatedWork W2888365383 @default.
- W2978374441 hasRelatedWork W2913735655 @default.
- W2978374441 hasRelatedWork W3047114976 @default.
- W2978374441 hasVolume "111" @default.
- W2978374441 isParatext "false" @default.
- W2978374441 isRetracted "false" @default.
- W2978374441 magId "2978374441" @default.
- W2978374441 workType "article" @default.